Featured Press Releases

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

  • 06 Nov 2024

Aadi Bioscience, Inc. announced financial results for the third quarter ended September 30, 2024,...

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research

FDA approves Apellis

FDA approves Apellis' EMPAVELI® (pegcetacoplan) as the first treatment for patients aged 12 and older with C3G and primary IC-MPGN

Osteo Bi-Flex® Adds Plant-Based Omega-3s to Promote Whole Body Health and Wellness

Osteo Bi-Flex® Adds Plant-Based Omega-3s to Promote Whole Body Health and Wellness

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

  • PHC Corporation
  • 08 Sep 2026
Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

  • Release Versions
  • 07 Sep 2026
New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

  • SQ Innovation
  • 02 Sep 2026
Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

  • Jarrow Formulas
  • 02 Sep 2026
Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

  • Abbott
  • 01 Sep 2026
Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

  • Karyopharm Therapeutics Inc.
  • 31 Aug 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.